CTRI/2020/11/029234进行中（未招募）2 期
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Centre Phase II/III Adaptive Clinical Trial to Assess the Safety and Immunogenicity of Gam-COVID-Vac Combined Vector Vaccine for SARS- Cov-2 Infection in Indian Healthy Subjects
Human Vaccine LLC0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Written informed consent of a subject to participate in the trial
- •2. Males and females aged 18+ years
- •3. Negative human immunodeficiency virus (HIV 1 & 2) and hepatitis B and C test results
- •4. Negative immunoglobulin M (IgM) and immunoglobulin G (IgG) SARS-CoV-2 antibodies through enzyme immunoassay test result
- •5. Negative COVID-2019 Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) test result at the screening visit (72 hours prior to Visit 1 [Day 1])
- •6. No COVID-2019 in the medical history
- •7. History of no contact with COVID-2019 persons within at least 14 days before the enrolment (according to subjects)
- •8. Consent for using effective methods of contraception during the entire trial1
- •9. Negative urine pregnancy test at the screening visit (for child-bearing age women)
- •10. No evident vaccine-induced reactions or complications after receiving immunobiological products in the medical history
- •11. No acute infectious and/or respiratory diseases within at least 14 days before the enrolment.
排除标准
- •1. Any vaccination/immunization within 30 days before the enrolment
- •2. Steroids (except hormonal contraceptives) and immunoglobulins or other blood products therapy not finished 30 days before the enrolment
- •3. Immunosuppressors therapy finished within 3 months before the enrolment
- •4. Pregnancy or breast-feeding
- •5. Acute coronary syndrome or stroke suffered less than one year before the enrolment
- •6. Tuberculosis, chronic systemic infections
- •7. Drug allergy (anaphylactic shock, Quincke edema, polymorphic exudative eczema, atopy, serum disease), hypersensitivity or allergic reaction to immunobiological products, known allergic reactions to study product components, acute exacerbation of allergic diseases on the enrolment day
- •8. Subjects who are on drugs that could have potential drug interactions with adenovirus vaccine
- •9. Medical history of malignancy
- •10. Donated blood or plasma (450+ mL) within 2 months before the enrolment
- •11. Splenectomy in the medical history
- •12. Neutropenia (absolute neutrophil count less than 1,000 mm3), agranulocytosis, significant blood loss, severe anaemia (haemoglobin less than 80 g/L), immunodeficiency including autoimmune disorders in the medical history within 6 months before the enrolment
- •13. Active form of a disease caused by the HIV and hepatitis B or C
- •14. Anorexia, protein deficiency of any origin
- •15. Tattoos at the injection site (deltoid muscle area), which does not allow assessing the local response to the IMP or placebo administration
- •16. Alcohol or drug addiction in the medical history.
- •17. Participation in any other interventional clinical trial within 1 month prior to the Screening
- •18. Any other medical condition that would limit the participation of the subject as per Investigator discretion
- •19. Study centre staff or other employees directly involved in the trial and their families
- •20. Subjects contraindicated for vaccination
研究者
相似试验
进行中（未招募）
1 期
A comparison study of LMTM and placebo in patients with mild Alzheimer's DiseaseEUCTR2012-002847-28-ESTauRx Therapeutics Ltd500
招募中
不适用
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 12-Month Trial of Leuco methylthioninium bis (hydromethanesulfonate) in Subjects with Mild to Moderate Alzheimer's DiseaseDiseases of the nervous systemKCT0001134TauRx Therapeutics88
进行中（未招募）
1 期
Study to evaluate the use of the investigational drug BIIB093 versus placebo in patients with a large hemispheric infarction.Cerebral edema following Large Hemispheric InfarctionMedDRA version: 20.0Level: LLTClassification code 10008107Term: Cerebral edemaSystem Organ Class: 100000004852EUCTR2017-004854-41-DKBiogen Idec Research Limited768
进行中（未招募）
1 期
A study to assess whether a drug called BHV-3241 works and is safe to use in people with Multiple System Atrophy (M-STAR Study)MedDRA version: 21.1Level: PTClassification code 10064060Term: Multiple system atrophySystem Organ Class: 10029205 - Nervous system disordersMultiple System AtrophyEUCTR2019-001100-38-ITBiohaven Pharmaceuticals, Inc.252
进行中（未招募）
1 期
Study to evaluate the use of the investigational drug BIIB093 versus placebo in patients with a large hemispheric infarction.Cerebral edema following Large Hemispheric InfarctionMedDRA version: 20.0Level: LLTClassification code 10008107Term: Cerebral edemaSystem Organ Class: 100000004852EUCTR2017-004854-41-ITBIOGEN IDEC RESEARCH LIMITED535